ArticleLeukemia research reports2026
Encouraging response rates and high mobilization success with brentuximab vedotin plus GDP in adult relapsed/refractory classical Hodgkin lymphoma: A real-world study.
Article in Leukemia research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Relapsed or refractory classical Hodgkin lymphoma (R/R cHL) remains challenging, and achieving metabolic complete response prior to autologous stem cell transplantation (ASCT) is important. GDP is a generally well-tolerated outpatient regimen, while brentuximab vedotin (BV) has demonstrated encouraging activity in salvage combinations. Adult real-world data on BV+GDP remain limited. Methods: Eight adult R/R cHL patients received BV+GDP between May 2023 and March 2025. Responses (Lugano 2014), toxicities (CTCAE v5.0), and mobilization outcomes were retrospectively evaluated. Results: Complete response was achieved in 7/8 patients (87.5%). All responders underwent successful stem-cell mobilization and ASCT. Toxicities were manageable, with no febrile neutropenia or renal toxicity observed. At a median follow-up of 10.6 months, all patients remained alive and progression-free. Conclusion: BV+GDP showed encouraging activity with acceptable tolerability, supporting further prospective evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.